24/7 Market News Snapshot 16 January, 2025 – BIOMERICA INC (NASDAQ:BMRA)

January 16, 2025

DENVER, Colo., 16 January, 2025 (247marketnews.com) – (NASDAQ:BMRA) are discussed in this article.
Biomerica Inc. is currently experiencing a significant surge in market activity, evidenced by its pre-market trading at $0.470, reflecting a notable 34.29% increase from the previous close of $0.350. This impressive performance is underscored by a trading volume of 10.31 million shares, indicating robust investor interest and confidence in the company’s growth potential. Analysts are closely monitoring this trend as Biomerica breaks through resistance levels, suggesting the possibility of further gains throughout the trading session.

In a strategic development, Biomerica has also announced the approval of its Fortel® Prostate Specific Antigen (PSA) Screening Test, a groundbreaking tool aimed at revolutionizing the early detection of prostate-related health conditions and addressing the pressing issue of prostate cancer. This innovative diagnostic solution delivers results within 10 minutes from a simple finger-prick blood sample, an advancement that has garnered the endorsement of the Ministry of Health and Prevention.

Prostate cancer remains one of the most prevalent cancers among men globally, with alarming statistics highlighting a diagnosis occurring every two minutes. Biomerica’s Fortel® PSA test is designed to empower healthcare providers and patients alike by enabling the swift identification of elevated PSA levels, a critical early indicator of prostate disease.

This new testing solution marks a strategic expansion into the Middle East, an area increasingly recognizing the importance of early cancer detection. Building on the established success of its EZ Detect Colon Disease At-Home Screening Test, which has already gained governmental insurance reimbursement, Biomerica aims to replicate this achievement with the Fortel® PSA test. Independent evaluations have showcased its impressive accuracy, with studies demonstrating 100% sensitivity and 95% specificity, confirming its reliability as a valuable diagnostic asset.

As Biomerica solidifies its commitment to improving health outcomes, the introduction of the Fortel® PSA test signifies a pivotal advancement in making sophisticated diagnostics more accessible and affordable, positioning the company as a leader in early cancer detection solutions.

Related news for (BMRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.